Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Biree Andemariam, MD
Healthcare Provider Associate Professor
Department of Medicine
UConn Health
263 Farmington Avenue
Farmington, Connecticut, United States
Dr. Biree Andemariam is a hematologist and founding director of the New England Sickle Cell Institute (NESCI) at the University of Connecticut Health Center. NESCI was established in 2009 and now serves nearly 300 adults living with sickle cell disease. With a staff of twelve individuals, including nurses, social workers, patient navigators, and research assistants, NESCI provides comprehensive care, acute pain management, specialized blood transfusions, and a destination for children in Connecticut who have aged out of pediatric SCD care.
Dr. Andemariam’s research focuses on developing new pathways of care that improve SCD care quality as well as translational research on deciphering the interplay between red blood cell adhesion to the walls of the circulatory system and the development of pain. She holds an undergraduate degree in molecular biology from Princeton University and a medical degree from Tufts. She is also the Chief Medical Officer of the Sickle Cell Disease Association of America, Inc.
Representative Publications:
Regulation of Active ICAM-4 on Normal and Sickle Cell Disease RBCs via AKAPs Is Revealed by AFM
+myBinderRelated Content
-
Allan F. Platt, MMSc, PA-C, DFAAPAAllan Platt has served as co-founder and...
-
Teens with Sickle Cell Disease Moving from Pediatric Care to Adult CareMoving from pediatric (children’s) car...
-
Integration of neuropsychology services in a sickle cell clinic and subsequent healthcare use for pain crisesObjective: Growing literature has docum...
-
Webinar Series: Sickle Cell Science: Path to Progress – Genetic Therapies in Sickle Cell DiseaseTo commemorate Sickle Cell Awareness Mon...
-
Children’s Hospital of WisconsinThe Sickle Cell Research Program at Chil...
-
Sickle Cell Disease Association of America Michigan Chapter, Inc.The vision of Sickle Cell Disease Associ...
-
FDA Approves Novel Treatment to Target Abnormality in Sickle Cell DiseaseToday, the U.S. Food and Drug Administra...
